- Latin for people = Latina pro populo.
- Ladies and Gentlemen of the Civil Service: Middle-Class Workers in Victorian America;
- Pharmacotherapy of obesity: Available medications and drugs under investigation..
- Balsamiq Wireframes Quickstart Guide.
- Proportional-integral-derivative control.
- Jazz keyboard harmony: a practical method for all musicians.
- Pharmacotherapy of Obesity: Options and Alternatives?
Endokrynologia Polska Open Journal Systems. Pharmacotherapy of obesity — state of the art. DOI: About this article. Obesity begets atrial fibrillation: a contemporary summary. Circulation , — Obesity and cardiovascular disease. Hvizdos, K. Orlistat: a review of its use in the management of obesity.
Drugs 58 , — Torgerson, J. XENical in the prevention of diabetes in obese subjects XENDOS study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27 , — Muls, E. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Heymsfield, S. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Weir, M. Orlistat and acute kidney injury: an analysis of patients.
Derosa, G. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Antel, J. Weight-reducing side effects of the antiepileptic agents topiramate and zonisamide. Allison, D. Obesity Silver Spring 20 , — Gadde, K. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults CONQUER : a randomised, placebo-controlled, phase 3 trial.
Lancet , — Garvey, W. Roberts, M. Sponsor: Vivus. Mines, D. Topiramate use in pregnancy and the birth prevalence of oral clefts.
You may also be interested in:
Drug Saf. Bialer, M. Pharmacokinetic interactions of topiramate. Grilo, C. Combining pharmacological and psychological treatments for binge eating disorder: current status, limitations, and future directions. Psychiatry Rep. Stanford, F.
Pharmacotherapy for Obesity.
The utility of weight loss medications after bariatric surgery for weight regain or inadequate weight loss: a multi-center study. Ojemann, L. Language disturbances as side effects of topiramate and zonisamide therapy. Epilepsy Behav.
PATIENT CARE PROCESS
Thomsen, W. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. Lam, D. Brain serotonin system in the coordination of food intake and body weight. Blundell, J. Serotonin, eating behavior, and fat intake. Fidler, M. Smith, S.
Multicenter, placebo-controlled trial of lorcaserin for weight management. O'Neil, P.
Pharmacotherapy for obesity: What you need to know
Kelly, M. Opioids hyperpolarize beta-endorphin neurons via mu-receptor activation of a potassium conductance. Neuroendocrinology 52 , — Greenway, F. Rational design of a combination medication for the treatment of obesity.
RACGP - Pharmacotherapy for obesity
Obesity Silver Spring 17 , 30—39 Future Cardiol. Jain, A. Bupropion SR versus placebo for weight loss in obese patients with depressive symptoms. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults COR-I : a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Wadden, T.
Obesity Silver Spring 19 , — Hollander, P. Diabetes Care 36 , — McElroy, S. Overview of the treatment of binge eating disorder. CNS Spectr. White, M. Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. Psychiatry 74 , — Yeomans, M. Opioid peptides and the control of human ingestive behaviour.
Calderone, A. Psychopathological behaviour and cognition in morbid obesity. Recent Pat. Immune Drug Discov. Astrup, A. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Pi-Sunyer, X. A randomized, controlled trial of 3.
- Recent advances and current trend in the pharmacotherapy of obesity Fasipe OJ - Arch Med Health Sci.
- Pharmacotherapy of obesity!
- Wake Unto Me?
- 1st Edition!
- Roy and Fraunfelders Current Ocular Therapy, 6Th Edition.
- Pharmacotherapy for Patients with Obesity | Clinical Chemistry.
Davies, M. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Chalmer, T. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes — focus on pancreatitis and pancreas cancer.
http://kp.wecan-group.com/nuevas-cartas-americanas-historia-n-405.php Funch, D. Diethylpropion and mazindol: an end to the discussion? Rev Assoc Med Bras. Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. Int J Obes.
Use of anti-obesity drugs among college students. Pharmacological treatment of the overweight patient. Pharmacol Rev. Voigt JP, Fink H. Serotonin controlling feeding and satiety.